Physician profile
Ari Young
NPI 1609220763
$4,042.62
in general payments reported to CMS, 2019-2025
31 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $242 · 2023: $808 · 2024: $1,293 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,800.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $954.79 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $826.84 | 2022-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $280.07 | 2023-2025 | |
| Janssen Biotech, INC. | $230.60 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $194.33 | 2023-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $193.89 | 2022-2024 | Sucraid, Sucraid |
| Lilly USA, LLC | $178.94 | 2023-2025 | Omvoh, Mounjaro, Zepbound |
| Celgene Corporation | $120.79 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $120.51 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $111.85 | 2024-2025 | Rebyota, Clenpiq |
| Ardelyx, INC. | $99.42 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $72.82 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $63.54 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $63.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $62.75 | 2022-2025 | Dupixent |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $54.97 | 2023 | Dificid |
| Celltrion USA INC. | $51.35 | 2025 | Vegzelma |
| Cequr Corporation | $43.80 | 2023-2024 | Cequr Simplicity |
| Radius Health, INC. | $40.60 | 2024 | Tymlos |
| Alvogen INC | $35.74 | 2023 | Teriparatide |
| Braintree Laboratories, INC. | $35.42 | 2023-2024 | Suflave |
| Laborie Medical Technologies Corp. | $31.79 | 2025 | |
| Intercept Pharmaceuticals, INC. | $29.07 | 2023 | Ocaliva |
| Insulet Corporation | $23.40 | 2023 | Omnipod |
| Biocon Biologics INC | $19.84 | 2025 | Yesintek |
| Exact Sciences Corporation | $19.16 | 2025 | The Cologuard Plus Collection Kit |
| Evoke Pharma, INC. | $18.56 | 2025 | |
| Organon LLC | $18.44 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.98 | 2023 | Adthyza |
| Mannkind Corporation | $15.35 | 2024 | |
| Novo Nordisk INC | $13.71 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.